Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Los Angeles Facial Plastic Surgeon Dr. Jacob Sedgh Recognized as a 2023 Top Patient Rated Doctor by Find Local Doctors


News Image

“It is such an honor to be recognized once again by Find Local Doctors. Providing my patients with beautiful, natural-looking results is always my goal,” says Dr. Sedgh.

A true leader in the world of aesthetic surgery, board-certified facial plastic surgeon, Dr. Jacob Sedgh, has impressive credentials and a superior level of training, coupled with a natural eye for balance and harmony. Dr. Sedgh offers his talent and skill to deliver excellence all areas of facial plastic surgery, ranging from traditional rhinoplasty procedures to reconstructive surgery on cancer patients. Find Local Doctors has selected Dr. Jacob Sedgh for this award as a result of his five-star ratings and exceptional reviews from patients across multiple online sources. Find Local Doctors is a user-friendly online directory, helps consumers connect with skilled physicians in their area. Dr. Sedgh has a deep understanding of facial aesthetics and consistently achieves results of outstanding quality that exceed the expectations of his patients. He provides a wide range of surgical and non-surgical treatments, which can often be combined to achieve optimal results, and he offers expertise in nose surgery (rhinoplasty), eyelid surgery (blepharoplasty), facelifts and ear surgery (otoplasty) and more. He has authored numerous medical articles and lectures at major seminars and conferences across the globe. Dr. Sedgh applies cutting-edge techniques to develop uniquely tailored treatments to address the specific needs of his patients.

“It is such an honor to be recognized once again by Find Local Doctors. Providing my patients with beautiful, natural-looking results is always my goal,” says Dr. Sedgh.

More about Dr. Jacob Sedgh:

With the benefit of two decades of medical training and practical experience at top medical institutions in the United States, Dr. Jacob Sedgh merges mastery of medical knowledge and surgical skills with the attention and perfection of a sculptor, delivering highly-personalized patient care. Dr. Sedgh attended the University of California, San Diego School of Medicine, receiving honors and recognition signifying his achievements as a top-tier graduate and completed a surgical internship at the University of California, San Francisco. He then finished his residency in otolaryngology and head and neck surgery at the prestigious University of Pittsburgh Medical Center, which is ranked third in the nation in head and neck surgery training. Patients can be confident they will receive the most advanced techniques and state-of-the-art technology from Dr. Sedgh at his clinic, located at 9201 Sunset Blvd, Suite 404 in West Hollywood, CA. For more information or to schedule a consultation, please call 310-888-2884 or visit http://www.sedghplasticsurgery.com.

Share article on social media or email:

Slone Partners Places Amy Levin as Vice President of Regulatory Affairs at Mainz Biomed


MainBiomed

“Amy Levin is an extremely accomplished and highly respected regulatory affairs specialist with a stellar history of high performance across multiple organizations,” said Slone Partners President Tara Kochis.

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Amy Levin as Vice President of Regulatory Affairs at Mainz Biomed, a biomedical company that develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

In her new role, Levin will be charged with guiding the implementation and regulatory, clinical trial, and quality initiatives that are related to in vitro diagnostics. She will also contribute to key milestones for the FDA submission process for ColoAlert, the company’s highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC).

Levin has a successful track record of leading and collaborating with cross-functional teams and regulatory authorities to author, manage, and review required reports of the U.S. Food and Drug Administration (FDA) and international regulatory submissions. Previously, she served as Director of International Regulatory Affairs at Roche Molecular Systems after serving in several other roles with increasing leadership responsibilities within the company. She has also held other regulatory positions at various biotechnology companies in the San Francisco Bay area.

“Amy Levin is an extremely accomplished and highly respected regulatory affairs specialist with a stellar history of high performance across multiple organizations,” said Slone Partners President Tara Kochis. “She is a smart and passionate leader who will be a tremendous addition to the Mainz Biomed team as it moves forward with its aggressive plans to bring ColoAlert to market in the U.S.”

“Ms. Levin is an outstanding addition to our executive team and is well known as a strategic thinker, methodical problem solver, and inclusive people manager who is results-oriented,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “With these strong attributes and extensive professional experience, she will help drive our internal processes to support operational excellence as we execute our clinical trials and work toward FDA submission and approvals in the U.S.”

“I have spent a majority of my career in regulatory affairs and am excited to use my expertise and in-depth knowledge of the regulatory guidelines, landscape and processes to further advance ColoAlert with a focus on the U.S. as its key market as well as the company’s portfolio of cancer detection products,” said Levin.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT MAINZ BIOMED NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter, and Facebook.

Share article on social media or email:



Mercury Insurance to Celebrate ‘Community Hero’ at LA Kings Home Games


It’s incredible to be a part of the passionate LA Kings community,” said Erik Thompson, vice president and Chief Marketing Officer at Mercury Insurance. We want our ‘Community Hero’ to know that Mercury appreciates them by giving each Hero the experience of a lifetime.

Mercury Insurance (NYSE: MCY) is continuing its 60 years celebration of service to Southern California communities by returning to the hockey rink with its 2022-23 Los Angeles Kings partnership. This marks the 15th consecutive year the two have teamed up to give fans and policyholders unique experiences inside and outside of games.

Mercury Insurance and the LA Kings this season are unveiling a fan favorite with a power-play twist, “My First Game” series. The series features Kings players reminiscing about their first games. It’s viewable at https://www.mercuryinsurance.com/campaigns/my-first/kings and Mercury invites fans to share in the fun with their own first game experiences on social media.

Mercury Insurance asked some fan favorites about their first game memories, including: LA-native Trevor Moore, Viktor Arvidsson, and Mikey Anderson:

  • Trevor Moore: “It was a Kings game. I remember coming through the concourse and the alley, then seeing the ice open up. It was pretty special. I was pretty young, but I remember how it made me feel.”
  • Viktor Arvidsson: “It was a group of 3-4 friends that always went to the game. In Sweden, you either sit or stand as a fan so we were always standing at the glass. Just a feeling of going there with my friends and having fun.”
  • Mikey Anderson: “It was a Minnesota Wild game. I was about 5 years old. My brother and I were wearing Marián Gáborík jerseys. We tried to go to as many of those [games] as we could.”

“It’s incredible to be a part of the passionate LA Kings community,” said Erik Thompson, vice president and Chief Marketing Officer at Mercury Insurance. “Mercury has planned a special program this season to coincide with our 60 years of serving Southern California communities. We’ll also be honoring unsung heroes at Kings’ home games for all the work they do in the community. We want our ‘Community Hero’ to know that Mercury appreciates them by giving each Hero the experience of a lifetime.”

The Community Hero is a chance for the Kings and Mercury, with the help of the Make-A-Wish Foundation, to honor those everyday heroes we don’t always know are right in front of us. The first Community Heroes are:

  • Ollie is a vibrant six-year-old from Valencia, California. Experiencing the magic of Disney World is his biggest wish. Ollie will be joined at the Kings game with his mom Marissa, dad Kyle, and sister Oakley.
  • Rachana Shah, MD, is the Director of the Cancer and Blood Disease Institute’s Retinoblastoma Program at Children’s Hospital Los Angeles. She helps care for many young children that develop cancer in the eye and is leading research in the field.

“The Kings are always looking for ways to honor the real heroes of the community,” said Luc Robitaille, President of the Los Angeles Kings. “We’re excited to showcase how these individuals lift their communities.”

For more information on this year’s sponsorship, please visit http://www.mercuryinsurance.com.

About Mercury Insurance

Mercury Insurance (NYSE: MCY) is a multiple-line insurance carrier predominantly offering personal auto, homeowners and renters insurance through a network of independent agents in Arizona, California, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas and Virginia, as well as auto insurance in Florida. Mercury writes other lines of insurance in various states, including commercial, business owners and business auto, landlord, home-sharing, ride-hailing and mechanical protection insurance.

Since 1962, Mercury has provided customers with tremendous value for their insurance dollar by pairing ultracompetitive rates with excellent customer service. Mercury has earned “A” ratings from A.M. Best and Fitch, as well as ranking highest in the J.D. Power 2021 U.S. Insurance Digital Experience Study,SM recognized as one of the “Best Insurance Company in America for 2022” by Forbes and four consecutive “Best Auto Insurance Company” awards from Insure.com. For more information visit http://www.MercuryInsurance.com or follow the company on Twitter or Facebook.

###

Share article on social media or email:

Syner-G BioPharma Group Acquires RMC Pharmaceutical Solutions


Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of RMC Pharmaceutical Solutions (RMC). Based in Boulder, CO, RMC supports the outsourced CMC and Quality needs of biotech and pharma companies across multiple therapeutic areas.

The acquisition provides additional depth to Syner-G’s suite of pharmaceutical science services, adding impressive development experience in all biologic modalities including cell and gene therapy. The combined team offers an impressive range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services. For RMC, the acquisition provides biotech and pharma clients access to a full range of integrated development and regulatory services.

Syner-G and RMC have strong records of consistent growth and success in providing customized solutions to support the development of life enhancing and lifesaving therapeutics. The combination enhances their ability to deliver the highest caliber CMC services to pharma and biotech companies of all sizes on a global basis.

“I am very pleased to welcome the RMC team to Syner-G,” said Ron Kraus, chief executive officer, Syner-G BioPharma Group. “RMC’s Biologics experience and their ‘Responsive, Measured, and Creative’ approach to product development fits perfectly with Syner-G’s vision to be the trusted development partner to our clients, recognized globally for our strategic, innovative, and scientifically-driven approach.”

Led by founders, Timothy Joy and Scott Rudge, RMC has provided practical and science-driven CMC and Quality solutions to its clients for over 18 years.

“Our clients have come to expect high levels of critical thinking, informed by the best science and engineering, applied reliably, nimbly, and phase appropriately to solve problems and advance their programs,” said Scott Rudge, co-founder, chairman, and chief operating officer of RMC. “We know that’s exactly what they will continue to receive from Syner-G and I’m delighted to continue to play a key role in the combined business.” Timothy Joy, co-founder, president, and chief executive officer of RMC added, “In addition to the obvious benefits the combined organization presents to RMC’s clients, I’m excited about the future opportunities that being part of a larger organization offers to the RMC team.”

Financial terms of the transaction, which closed in January 2023, were not disclosed.

About Syner-G BioPharma Group

Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, visit http://www.synergbiopharma.com.

About RMC Pharmaceutical Solutions

Based in Boulder, CO, RMC specializes in providing CMC and quality management services for the pharmaceutical and biotech sector. For more information, visit http://www.rmcpharma.com.

Share article on social media or email:

Piezo Therapeutics Launches to Transform Delivery of Nucleic Acid Medicines


News Image

Piezo Therapeutics is advancing a novel delivery platform to improve the safety, affordability, and scalability of nucleic acid medicines.

Piezo Therapeutics launched with $2 million in seed funding from Open Philanthropy to develop its platform: a simple and affordable way of delivering RNA and DNA medicines, including vaccines and therapeutic proteins. Piezo’s platform combines electric pulses and microneedles to deliver nucleic acid medicines safely and efficiently while accelerating manufacturing, easing access, and minimizing costs.

“The COVID-19 pandemic has enabled incredible advances in mRNA vaccines and potential for future RNA therapeutics. However, these RNA-based medicines still face challenges with manufacturing, thermostability, safety, and access,” said Gaurav Byagathvalli, co-founder and CEO. “Piezo has a unique opportunity to address these challenges with a simple, affordable, and scalable platform enabling further translation of RNA, DNA, and other therapeutics.”

Novel Platform Building on Decades of Data

Piezo’s platform combines two key technologies that have been validated in pre-clinical and clinical models for over 25 years, namely the use of electric pulses and microneedles for drug delivery. Electric pulses have been shown to enhance gene expression of RNA and DNA constructs by 100-1000-fold, while microneedles have demonstrated painless and effective delivery of a broad range of biologics.

Current modes of administering electric pulses have numerous limitations associated with cost, manufacturing, patient administration, and tolerability, which have hindered their translation. “Piezo’s key innovation in generating electric pulses addresses each of these challenges,” said Mark Prausnitz, co-founder. “And when combined with microneedles, our technology enables improved safety and efficacy in a simple and scalable format.”

“We are excited about our partnership with Open Philanthropy, and our shared mission to improve patient access to these innovative treatments, globally,” said Saad Bhamla, co-founder.

Company Vision and Leadership

RNA therapeutics have made major advances but suffer from limitations associated with their delivery in the body. While lipid nanoparticles are used in current COVID vaccines, they present issues including high cost, manufacturing complexity, and poor stability. Electric pulses can also provide effective delivery, but current approaches involve devices that have even higher costs and complexity.

To enable next-generation RNA and DNA medicines, Piezo is advancing its platform integrating a piezoelectric pulse generator and microneedles to address these challenges.

While this platform has high applicability for vaccines (Piezo’s immediate focus), it is designed for a broad array of nucleic acid therapeutics. Piezo plans to partner with a range of companies across diverse therapeutic modalities including vaccines, immunotherapies, therapeutic proteins, and dermal gene therapies.

Piezo will be led by Gaurav Byagathvalli, who will serve as chief executive officer and a member of the board of directors.

Piezo’s highly experienced board of directors also includes:


  • Mark Prausnitz, Ph.D.: Prausnitz is a Regents’ Professor and Regents’ Entrepreneur in Chemical & Biomolecular Engineering at Georgia Tech. He is a Fellow of the National Academy of Inventors and has co-founded eight privately held or publicly traded companies in pre-clinical, clinical and product stages of commercialization.
  • Saad Bhamla, Ph.D.: Bhamla is an Assistant Professor of Chemical & Biomolecular Engineering at Georgia Tech. He is a prolific inventor and has developed numerous biomedical devices with applications in global health.
  • Cynthia Sundell, Ph.D.: Sundell has over 15 years drug development executive management experience in the US and Europe. She is currently a Principal in Georgia Tech’s VentureLab where she stewards promising commercialization opportunities arising from Georgia Tech’s life science intellectual property portfolio.


To support the development and translation of Piezo-delivered medicines, the company is conducting pre-clinical studies in collaboration with academic institutes, while working with industry partners to co-develop products that deliver their therapeutics with Piezo’s technology.

About Piezo Therapeutics

Piezo Therapeutics aims to transform the delivery of nucleic acid medicines to enable improved safety, affordability, and scalability. Piezo is developing a uniquely engineered platform that uses electric pulses and microneedles to deliver a broad range of therapeutics inside the body. Its piezoelectric technology offers improved safety and efficacy, and is simple, cost-effective, and rapid to produce at scale. Founded by experts in the field of drug delivery and commercial translation, Piezo’s diverse team aims to help translate the next generation of nucleic acid medicines. For more information, please visit http://www.piezotx.com or email partnerships@piezotx.com.

Share article on social media or email:

Oshi Health Adds Distinguished Physician-Scientist and Upcoming AGA President Dr. Maria T. Abreu to Medical Advisory Board


“If we want to change the course of IBD on a larger scale, we need to be able to offer multidisciplinary, integrated, high-quality care. Oshi Health has demonstrated its commitment to integrated care delivery models to reduce costs and improve outcomes,” said Dr. Abreu.

Crohn’s and Colitis Congress – Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that Dr. Maria T. Abreu of University of Miami’s Miller School of Medicine and upcoming President of the American Gastroenterological Association (AGA) has joined its medical advisory board.

Dr. Abreu is an internationally renowned physician-scientist. The Abreu lab at the University of Miami has focused on the relationship between the host innate immune response and the microbiome in perpetuating IBD and its complications. Her laboratory leads pioneering research into the genetic and environmental factors that contribute to the development of IBD, including the first description of the phenotype in Hispanic patients and characterizing the genetics of their disease, as well as building one of the largest biorepositories of tissue specimens that has already supported significant research advances.

Dr. Abreu is most known for leading groundbreaking IBD research in Miami’s Hispanic population aimed at understanding the rising epidemic of disease in today’s first-generation immigrants, who are developing IBD much more quickly than previous generations. Her team has recently received an NIH grant to look at the genetic architecture of Hispanic people with IBD. As a result of her interest in modifying the risk of IBD and improving quality of life in patients, her team has embarked on a landmark study combining diet intervention with behavioral psychology approaches to change the way IBD patients and their families eat. These studies have implications for a wide IBD patient population.

“Understanding and treating IBD requires looking at everything going on with a patient, as an interconnected whole. The desire to help individual IBD patients in a comprehensive way is challenged by insufficient time and resources by most clinicians. If we want to change the course of IBD on a larger scale, we need to be able to offer multidisciplinary, integrated, high-quality care. Oshi Health has demonstrated its commitment to a data-driven approach that uses integrated care delivery models to reduce costs and improve outcomes,” said Dr. Abreu. “Together we can drive better outcomes for patients which, in turn, will allow investing resources into the things that patients care about such as living a predictable, normal life, having families, and going to work. Our patients don’t want to have visits to the ER or the hospital. They want a knowledgeable health team that will be proactive in their care.”

As a virtual multidisciplinary digestive care clinic, Oshi Health extends community GI practices coping with long wait times for appointments and overwhelming demand from patients by delivering high-touch support and addressing ancillary concerns like mental health, nutrition, and care plan questions, so that practices can focus their capacity on delivering necessary in-person care. Patients have access to a team of GI-specialized professionals including gastroenterologists, nurse practitioners, licensed psychologists, social workers, dietitians, and health coaches that support behavior change and care plan compliance.

By delivering clinically appropriate interventions through the convenience of telehealth and digital tools, Oshi Health empowers people to understand their condition and triggers, and reclaim their lives from chronic debilitating symptoms. Ninety-one percent of Oshi Health members achieve symptom control in 4 months or less, in turn, driving a 98% member satisfaction level.

“I am thrilled to partner with Dr. Abreu to build a world where every single patient with IBD has access to comprehensive, evidenced-based, multidisciplinary GI care,” said Dr. Sameer Berry, Chief Medical Officer of Oshi Health. “She has the rare combination of research and clinical expertise in IBD, along with a pragmatic approach to building the future of care delivery in gastroenterology. I am most excited to partner with Dr. Abreu on designing culturally-informed care protocols to care for traditionally marginalized patient populations, who would benefit most from access to multidisciplinary care.”

Dr. Abreu is widely known as one of the foremost experts in IBD. She has authored more than 300 peer-reviewed publications and trained many gastroenterologists who are leaders in their respective subspecialities. She is the Director of the Crohn’s and Colitis Center at the University of Miami, the past chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), and recipient of the prestigious 2019 Sherman Prize – an award given to the nation’s preeminent IBD researchers. Dr. Abreu was recently elected Vice President of the American Gastroenterological Association (AGA) and will assume the role of President in 2024 to lead more than 16,000 gastroenterologists in the U.S.

Dr. Abreu joins fellow Oshi Health advisory board members Gil Melmed, MD, MS, of Cedars-Sinai in Los Angeles, and Dr. John Allen, retired Chief Clinical Officer at the University of Michigan Medical Group and past President & Chairman of the American Gastroenterological Association (AGA).

About Oshi Health

Oshi Health is a completely redesigned digestive health care experience that transforms access to care, the patient experience, clinical outcomes and healthcare economics. In a high-touch virtual care delivery model, Oshi Health provides diagnosis and integrated care for digestive conditions and empowers people to achieve lasting control of their symptoms. Launched in 2020, Oshi Health works with innovative employers, health insurance partners, health systems and community GI practices to scale access to multidisciplinary care, reduce healthcare costs, and improve the lives of millions of Americans with chronic gastrointestinal diseases. For more information, visit http://www.oshihealth.com.

Share article on social media or email:

Atlanta Plastic Surgery, P.C. Surgeons Play Prominent Role in 38th Annual Internationally Acclaimed Breast Surgery Symposium January 27th-29th, 2023


News Image

The Southeastern Society of Plastic and Reconstructive Surgeons and Northside Hospital are hosting the 38th annual Breast Surgery Symposium from January 27th through January 29th, 2023 at the Intercontinental Hotel in Buckhead. This year three top surgeons from Atlanta Plastic Surgery, Program Chair James Namnoum, M.D., and Program Co-Chair Franklyn Elliott, M.D. and Jonathan Nguyen, M.D (board-eligible). will have prominent roles in the three-day scientific program.

The late Dr. Carl Hartrampf, the co-Founder of Atlanta Plastic Surgery, originated the three-day Breast Surgery Symposium in 1984. Since then the Symposium has grown to include nearly 500 registrants from 15 countries and has become internationally synonymous with innovations in reconstructive and cosmetic breast surgery. This year Dr. Robert J. Allen, M.D., Clinical Professor of Plastic Surgery at Louisiana State University, will deliver the Honorary Hartrampf Lecture on “The Marriage of Beauty and Blood Supply.”

The Atlanta Breast Surgery Symposium’s agenda will begin with live demonstrations of the most advanced surgical techniques transmitted from Northside Hospital to meeting attendees at the Intercontinental Hotel. Other live telecast surgeries will feature secondary breast augmentation with mesh and trans abdominal breast augmentation.

Dr. Nguyen (board-eligible) from Atlanta Plastic Surgery will assist in one of the Symposium’s two live surgery telecasts. This telecast features gender affirming mastectomy by Dr. Loren Schechter, Director of Gender Affirming Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Nguyen(board-eligible)is Atlanta Plastic Surgery‘s newest surgeon.

The symposium will also feature comprehensive panels discussing autologous fat grafting, prosthetic based breast reconstruction, and revisional breast surgery. Symposium panels will discuss current trends and techniques in breast surgery, breast implants, breast augmentation, mastectomy, oncoplastic surgery, and breast reconstruction. Other panels will discuss reduction Mastopexy, moderated by Dr. Elliott with a presentation by Dr. Namnoum on Mastopexy: Breast Transformation by a Comprehensive Approach. Dr. Elliott will also moderate a Breast Implant Panel.

About Atlanta Breast Symposium: An educational three day conference geared toward advancing the knowledge and skill of all aesthetic and reconstructive breast surgeons, the Atlanta Breast Surgery Symposium was formed in 1984 by the late Dr. Carl Hartrampf, co-Founder of Atlanta Plastic Surgery. It is hosted every January by the Southeastern Society of Plastic and Reconstructive Surgeons (SESPRS) and sets the precedence for breast surgery advancements. Visit sesprs.org for symposium details.

About Atlanta Plastic Surgery: Atlanta Plastic Surgery, P.C. was founded in 1968 by the late Dr. Carl Hartrampf. Our staff of surgeons have achieved international reputations in their specialties through published books, papers, lectures and live surgical demonstrations. Because each of Atlanta Plastic Surgery’s physicians have different areas of concentration, they can provide unparalleled scope, expertise and specialization in cosmetic and plastic surgery procedures. For more information, visit their website at atlplastic.com.

Share article on social media or email:

Santé Center for Healing’s Announces Collegiate Scholarship Recipients


Helping collegiates specifically in recovery from addiction and/or specifically wanting to pursue a degree in these important fields aligns with Santé’s core values.

Santé Center for Healing is honored to announce three recipients of our annual collegiate scholarships. Pictures of the recipients are available upon request. The Deb Corley & Santé Center for Healing Scholarship is in honor of Santé’s co-founder/co-owner Dr. Deb Corley, PhD, LMFT, LCDC, LSOTP, CSAT, CMAT. Recipients of this scholarship are pursuing a graduate degree towards work in the mental and behavioral health field.


  • Brittany David of Fresno, CA attending College of William and Mary

The Rip Corley & Santé Center for Healing Scholarship is in memory of Santé’s co-founder Rip Corley, LMSW, RN. Recipients of this scholarship are individuals in recovery from addiction for at least two years, having completed at least one year in college and pursuing an undergraduate degree from an accredited college and/or university.

  • Mason Collie of Houston, TX attending University of Houston
  • Carey Price of Fort Worth, TX attending Weatherford College

“We offer these collegiate scholarships with the desire to assist individuals who are working to further their education. Helping collegiates specifically in recovery from addiction and/or specifically wanting to pursue a degree in these important fields aligns with Santé’s core values,” says Santé’s CEO Sam Slaton, M.ED, LPC-S, MBA, MHSM. “Providing assistance to those entering this field is a privilege.” In 2021, 46.3 million people aged 12 or older (or 16.5 percent) had a substance use disorder in the past year, including 29.5 million who had an alcohol use disorder, 24.0 million who had a drug use disorder, and 7.3 million people who had both an alcohol use disorder and a drug use disorder. Nearly half of young adults aged 18 to 25 in 2021 (45.8 percent or 15.3 million people) had either a substance use disorder or any mental illness in the past year. This percentage was higher than corresponding percentages among adults aged 26 to 49 (39.5 percent or 40.4 million people) and adults aged 50 or older (22.6 percent or 26.7 million people). And in 2021, 18.8 percent of adults aged 18 or older (or 46.5 million people) received any of the following mental health services in the past year: inpatient or outpatient mental health services, prescription medication for a mental health issue, or virtual (i.e., telehealth) services.(1) It is vital to have qualified individuals in the fields of mental and behavioral health and health care management. About [Santé Center for Healing]: Santé Center for Healing provides integrity-driven, evidence-based, and personalized long-term recovery for those suffering from substance use disorders, mental health, trauma, problematic sexual behavior, co-occurring disordered eating and other compulsive behaviors. For more information visit http://www.santecenter.com.1. Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report

Share article on social media or email:

Joint statement by The European Disability Forum and The International Disability Alliance on the blockade of the Lachin Corridor, Nagorno-Karabakh


"Joint statement by the International Disability Alliance and European Disability Forum regarding the blockade of the Lachin Corridor, Nagorno-Karabakh" set against a blue background. In the background, you can barely make out a photo of the tents in the Lachin Corridor. Below the text, there are the logos of the IDA and EDF on a white background.

As a result of the blockade of the Lachin Corridor, the lifeline road connecting Nagorno-Karabakh to Armenia, around 120,000 people, including more than 9,000 persons with disabilities face grave human rights violations.

As a result of the blockade, around 120,000 people, including more than 9,000 persons with disabilities, face grave human rights violations. This includes the denial of their freedom of movement as about 1,100 people cannot return to their homes in Nagorno-Karabakh, including 270 children separated from their parents.

Children’s right to an inclusive education has been disrupted because kindergartens and preschools have been closed due to the insecurity of the food supply.

Due to the closure of the road, access to essential goods and services in the region has become impossible. Shops are mostly empty, and medicine, including for children and persons with long-term medical conditions, are largely unavailable. There are reports of children being given adult medicines due to these shortages.

The situation is particularly challenging for persons with disabilities living in residential institutions because the issue of access to medicine is getting worse from day to day and food supplies are especially limited for people who have special dietary requirements.

People in need of urgent medical assistance, whose treatment cannot be organized in Nagorno Karabakh, can be transferred to Armenia, but only with the help of the International Committee of the Red Cross.

We, the undersigned organizations, call on all parties to fulfill all their obligations according to the United Nations Convention on the Rights of Persons with Disabilities and the Security Council Resolution 2475. The Government of Azerbaijan and the peacekeeping contingent of the Russian Federation must immediately unblock the Lachin Corridor in accordance with paragraph 6 of the November 9, 2020, Trilateral Statement. We call for the unimpeded humanitarian access as well as freedom of movement along the Lachin Corridor, in both directions, for all civilians, to ensure safe, timely and unlimited humanitarian assistance for all.

We call on the authorities of Armenia to take all necessary measures to ensure fulfilling human rights of those who cannot return to Nagorno-Karabakh, providing them with accessible conditions and reasonable accommodations. We call on all leaders in the region to work together towards a peaceful solution to prevent military escalation of the conflict and help facilitate peace negotiations.

We call on humanitarian actors and human rights organizations to provide adequate assistance to people with disabilities in the region, meaningfully considering gender and age differences as stipulated in the international standards including the Inter-Agency Standing Committee Guidelines on Inclusion of Persons with Disabilities in Humanitarian Action.

The meaningful participation of persons with disabilities and their representative organizations in the conflict prevention and resolution processes should be assured to ensure that the human rights of persons with disabilities are protected, promoted and prioritized.

Signed by:

The European Disability Forum

The International Disability Alliance (IDA)

Share article on social media or email:

Juno Diagnostics™ Launches Its Early At-Home Gender Test on Amazon Prime


News Image

With a few drops of maternal blood, we can examine DNA from your pregnancy and determine whether you’re expecting a boy or a girl.

Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving accessibility, affordability, and transparency, is announcing the launch of its Juno Birch™ Fetal Gender Test on Amazon.

With the test now available on Amazon, pregnant women do not have to wait until their 20-week anatomy ultrasound or a gender sonogram to find out their baby’s fetal sex. The Juno Birch™ Test combines clinical quality testing with at-home convenience. The testing kit includes everything needed to collect a sample in just a few minutes. The sample is then mailed to the JunoDx lab with a prepaid two-day shipping label, and baby gender results are provided within two business days.

“With a few drops of maternal blood, we can examine DNA from your pregnancy and determine whether you’re expecting a boy or a girl,” said Dirk van den Boom, co-founder and Chief Executive Officer of JunoDx™.

With more than a decade of cell-free DNA testing experience, the JunoDx team delivers the world’s most advanced Fetal Gender Test. Our >99% test accuracy is based on results from actual at-home blood collection and was created by the same team that developed the first non-invasive prenatal screening test in the U.S.

To learn more about the Juno Birch™, visit https://www.amazon.com/stores/page/3EFE4E42-D603-45A2-8A3C-EAF4CD463FDC?ingress=0&visitId=b7f73c21-e6a2-41b2-af24-5e99f3f7a73c.

About Juno Diagnostics™

Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining accessibility, affordability, and transparency. The Company has developed a proprietary Sample Collection Kit and Device to facilitate capillary blood-based testing. Its lead product, the Juno Hazel™ test, is a non-invasive prenatal screening (NIPS) test that utilizes the proprietary Sample Collection Kit and improves access to high-quality testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS.

For more information, visit http://www.junodx.com and engage with us on LinkedIn.

Share article on social media or email: